Share this article

print logo

Cleveland BioLabs seeks to stockpile anti-radiation drug

Cleveland BioLabs’ bid to gain federal approval so that its anti-radiation sickness drug can be stockpiled for use in an emergency, such as a terrorist attack or nuclear power plant accident, took a step forward Monday with the Buffalo drug development company submitting its application to regulators.

The application to the Food and Drug Administration seeks permission for Cleveland BioLabs’ Emtolimod drug to be used as an emergency treatment for radiation sickness – a step executives at the cash-strapped company believe is the fastest way for its most advanced drug candidate to begin generating revenue.

But even if Entolimod gains approval under the FDA’s pre-Emergency Use Authorization process, it likely will take six months to nine months for federal regulators to complete their evaluation, which would push the launch date for the drug’s first potential sales as a radiation countermeasure into early 2016.